Advertisement

Pediatric Nephrology

, 21:766 | Cite as

Type IV Bartter syndrome: report of two new cases

  • Marco Zaffanello
  • Anna Taranta
  • Alessia Palma
  • Alberto Bettinelli
  • Gian Luigi Marseglia
  • Francesco Emma
Original Article

Abstract

Bartter syndrome with sensorineural deafness (type IV Bartter syndrome) is a subtype of this tubular disease, and is due to mutations in the BSND gene. Out of a population of 92 patients with Bartter syndrome, five suffered from mild to severe hypoacusia and were selected for mutational screening. A homozygous mutation in the BSND gene was found in two female patients. The first patient was found to have a substitution in intron 1 donor splice site at position +5 (c.420+5G>C), whereas the second patient has a homozygous 3G>A substitution leading to the loss of the start codon for the translation of the BSND mRNA. The clinical courses of these two patients were remarkable for severe polyhydramnios, massive renal salt and water wasting, severe neonatal hypotonia, poor growth and unresponsiveness to prostaglandin inhibitors. The diuretic responses to furosemide and to hydrochlorothiazide were tested under KCl supplementation in one patient. A lack of response to both drugs suggested that inhibition of NaCl reabsorption in type IV Bartter syndrome is not restricted to the thick ascending limb of Henle. In one patient, a combined therapy with indomethacin and captopril was needed to discontinue intravenous fluids and improve weight gain.

Keywords

Bartter syndrome Sensorineural deafness Captopril Indomethacin Nimesulide Furosemide Hydrochlorothiazide 

References

  1. 1.
    Konrad M, Weber S (2003) Recent advances in molecular genetics of hereditary magnesium-losing disorders. J Am Soc Nephrol 14:249–260PubMedCrossRefGoogle Scholar
  2. 2.
    Birkenhager R, Otto E, Schurmann MJ, Vollmer M, Ruf EM, Maier-Lutz I, Beekmann F, Fekete A, Omran H, Feldmann D, Milford DV, Jeck N, Konrad M, Landau D, Knoers NV, Antignac C, Sudbrak R, Kispert A, Hildebrandt F (2001) Mutation of BSND causes Bartter syndrome with sensorineural deafness and kidney failure. Nat Genet 29:310–314PubMedCrossRefGoogle Scholar
  3. 3.
    Brennan TM, Landau D, Shalev H, Lamb F, Schutte BC, Walder RY, Mark AL, Carmi R, Sheffield VC (1998) Linkage of infantile Bartter syndrome with sensorineural deafness to chromosome 1p. Am J Hum Genet 62:355–361PubMedCrossRefGoogle Scholar
  4. 4.
    Vollmer M, Jeck N, Lemmink HH, Vargas R, Feldmann D, Konrad M, Beekmann F, van Den Heuvel LP, Deschenes G, Guay-Woodford LM, Antignac C, Seyberth HW, Hildebrandt F, Knoers NV (2000) Antenatal Bartter syndrome with sensorineural deafness: refinement of the locus on chromosome 1p31. Nephrol Dial Transplant 15:970–974PubMedCrossRefGoogle Scholar
  5. 5.
    Estevez R, Boettger T, Stein V, Birkenhager R, Otto E, Hildebrandt F, Jentsch TJ (2001) Barttin is a Cl channel beta-subunit crucial for renal Cl reabsorption and inner ear K+ secretion. Nature 414:558–561Google Scholar
  6. 6.
    Landau D, Shalev H, Ohaly M, Carmi R (1995) Infantile variant of Bartter syndrome and sensorineural deafness: a new autosomal recessive disorder. Am J Med Genet 59:454–459PubMedCrossRefGoogle Scholar
  7. 7.
    Colussi G, Rombola G, Brunati C, De Ferrari ME (1997) Abnormal reabsorption of Na+/CI by the thiazide-inhibitable transporter of the distal convoluted tubule in Gitelman’s syndrome. Am J Nephrol 17:103–111PubMedCrossRefGoogle Scholar
  8. 8.
    Nusing RM, Reinalter SC, Peters M, Komhoff M, Seyberth HW (2001) Pathogenetic role of cycloxygenase-2 in hyperprostaglandin E sindrome/antenatal nBartter sindrome: therapeutic use of the cycloxygenase-2 inhibitor nimesulide. Clin Pharmacol Ther 70:384–390PubMedGoogle Scholar
  9. 9.
    Schlingmann KP, Konrad M, Jeck N, Waldegger P, Reinalter SC, Holder M, Seyberth HW, Waldegger S (2004) Salt wasting and deafness resulting from mutations in two chloride channels. N Engl J Med 25:1314–1319CrossRefGoogle Scholar
  10. 10.
    Shalev H, Ohali M, Kachko L, Landau D (2003) The neonatal variant of Bartter syndrome and deafness: preservation of renal function. Pediatrics 112:628–633PubMedCrossRefGoogle Scholar
  11. 11.
    Mendoza SA (1988) Nephrotoxic drugs. Pediatr Nephrol 2:466–476PubMedCrossRefGoogle Scholar
  12. 12.
    Reinalter SC, Grone HJ, Konrad M, Seyberth HW, Klaus G (2001) Evaluation of long-term treatment with indomethacin in hereditary hypokalemic salt-losing tubulopathies. J Pediatr 139:398–406PubMedCrossRefGoogle Scholar
  13. 13.
    Harris RC, Breyer MD (2001) Physiological regulation of cyclooxygenase-2 in the kidney. Am J Physiol Renal Physiol 281:F1–F11PubMedGoogle Scholar
  14. 14.
    Waldegger S, Jeck N, Barth P, Peters M, Vitzthum H, Wolf K, Kurtz A, Konrad M, Seyberth HW (2002) Barttin increases surface expression and changes current properties of ClC-K channels. Eur J Physiol 444:411–418CrossRefGoogle Scholar
  15. 15.
    Reinalter SC, Jeck N, Peters M, Seyberth HW (2004) Pharmacotyping of hypokalaemic salt-losing tubular disorders. Acta Physiol Scand 181:513–521PubMedCrossRefGoogle Scholar

Copyright information

© IPNA 2006

Authors and Affiliations

  • Marco Zaffanello
    • 1
    • 2
  • Anna Taranta
    • 1
  • Alessia Palma
    • 1
  • Alberto Bettinelli
    • 3
  • Gian Luigi Marseglia
    • 4
  • Francesco Emma
    • 1
  1. 1.Division of Nephrology and Dialysis, Department of Nephrology and UrologyOspedale Bambino GesùRomeItaly
  2. 2.Department of PaediatricsUniversity of VeronaVeronaItaly
  3. 3.Department of PediatricsSan Leopoldo Mandic’s HospitalMerate (Lecco)Italy
  4. 4.Department of PediatricsUniversity of PaviaPaviaItaly

Personalised recommendations